Forebyggelse af herpes zoster med vaccination
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Forebyggelse af herpes zoster med vaccination. / Kofoed, Kristian; Rønholt, Finn; Gerstoft, Jan; Sand, Carsten.
In: Ugeskrift for Laeger, Vol. 173, No. 2, 10.01.2011, p. 110-4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Forebyggelse af herpes zoster med vaccination
AU - Kofoed, Kristian
AU - Rønholt, Finn
AU - Gerstoft, Jan
AU - Sand, Carsten
PY - 2011/1/10
Y1 - 2011/1/10
N2 - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.
AB - Herpes zoster (HZ) and post-herpetic neuralgia (PHN) are frequently occurring diseases in elderly and in immuno-compromised persons. The live attenuated HZ vaccine boosts an existing immune response, so that the already established varicella-zoster virus infection is kept latent. Vaccination has been shown to halve the risk of HZ, and the risk of PHN is reduced by two thirds in people = 60 years. The vaccine is approved for persons aged = 50 years. However, the clinical efficacy of the vaccine is best studied in people aged = 60 years. The vaccine has so far not shown any serious side-effects.
M3 - Tidsskriftartikel
VL - 173
SP - 110
EP - 114
JO - Ugeskrift for Laeger
JF - Ugeskrift for Laeger
SN - 0041-5782
IS - 2
ER -
ID: 40154850